Greenwich LifeSciences Reports 83% Drop In Breast Cancer Recurrence; Stock Up

GLSI reported Phase 3 FLAMINGO-01 data showing breast cancer recurrence rates in one arm fell to under 1% per year for its immunotherapy candidate GLSI-1. This result from a Phase 3 cohort materially de-risks the program and could meaningfully increase the therapy's clinical and commercial prospects if replicated across arms. The data is a significant positive catalyst for Greenwich LifeSciences but remains contingent on full trial readouts and regulatory review.

Analysis

GLSI reported Phase 3 FLAMINGO-01 data showing breast cancer recurrence rates in one arm fell to under 1% per year for its immunotherapy candidate GLSI-1. This result from a Phase 3 cohort materially de-risks the program and could meaningfully increase the therapy's clinical and commercial prospects if replicated across arms. The data is a significant positive catalyst for Greenwich LifeSciences but remains contingent on full trial readouts and regulatory review.